U030 Managing Unique Conditions in Asian Skin
DESCRIPTION
Open admission to eligible categories, no tuition or ticket
Asians constitute over 60% of the world's population. The percentage of the United States population identifying as Asian is expected to double by the year 2050. Consequently, the demand for dermatologic care from this demographic will increase, requiring dermatologists to become more familiar with the diagnosis and treatment of Asian-specific skin diseases and cosmetic concerns. We will explore the characteristics of Asian skin and offer clinical pearls for diagnosing and managing prevalent skin concerns among Asian patients, including Riehl's melanosis, Hori's nevus, melasma, acral and nail melanoma, and scars.
LEARNING OBJECTIVES
Recognize unique characteristics of Asian skin.
Manage pigmentary disorders and scarring disorders in patients with Asian skin.
Summarize unique presentation of common skin disorders in Asian skin.
SCHEDULE
3:30 PM
Insights into Asian Skin: Characteristics and Clinical Pearls
Hye Jin Chung, MD, FAAD
3:40 PM
Diagnostic approach for early detection of acral and nail unit melanoma in Asians
Mi Ryung Roh, MD, PhD
3:55 PM
Practical approach to common facial pigmented lesions in Asians
Woraphong Manuskiatti, MD
4:15 PM
Approach To Scars In Asian Patients In 2024
Omar Ibrahimi, MD, PhD, FAAD
4:25 PM
Q&A
SPEAKERS
Hye Jin Chung, MD, FAAD
Omar Ibrahimi, MD, PhD, FAAD
Woraphong Manuskiatti, MD
Mi Ryung Roh, MD, PhD
HANDOUTS
SPEAKER DISCLOSURES
Hye Jin Chung, MD, FAAD
Lutronics, Inc. – Consultant(No Compensation Received); Regeneron Pharmaceuticals, Inc. – Investigator(Grants/Research Funding); Sonoma Pharmaceuticals – Advisory Board(No Compensation Received);
Omar Ibrahimi, MD, PhD, FAAD
AbbVie – Stockholder(Stock); Accure, Inc – Advisory Board(No Compensation Received); Acure Acne – Stockholder(Stock); Allergan, Inc – Advisory Board(Honoraria); AVAVA, LLC – Investigator(Grants/Research Funding), Stockholder(Stock); Beam Therapeutics – Stockholder(Stock); ChromaDex Corp. – Stockholder(Stock); CRISPR Therapeutics – Stockholder(Stock); Cutera, Inc. – Speaker(Honoraria); Cytrellis Biosystems, Inc – Advisory Board(Honoraria); Editas Medicine – Stockholder(Stock); General Electric – Stockholder(Stock); Gingko Bioworks Holding Inc – Stockholder(Stock); Intellia Therapeutics – Stockholder(Stock); Lutronic – Advisory Board(Honoraria); Moderna Therapeutics – Stockholder(Stock); Pfizer Inc. – Stockholder(Stock); Procter & Gamble Company – Stockholder(Stock); Regeneron Pharmaceuticals, Inc. – Stockholder(Stock); Revance Therapeutics, Inc. – Stockholder(Stock); Soltego – Stockholder(Stock); Unilever – Stockholder(Stock); Vertex Pharmaceuticals, Inc. – Stockholder(Stock); Viatris Inc. – Stockholder(Stock);
Woraphong Manuskiatti, MD
No financial relationships exist with ineligible companies.
Mi Ryung Roh, MD, PhD
No financial relationships exist with ineligible companies.